

SESSIONS

BIOTECH SHOWCASE 2018 - SUNDAY REGISTRATION - 07/01/2018

Biotech Showcase

January 8-10, 2018

HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Registration Opens

3:00pm - 6:00pm

Hilton, Plaza on the lobby level and Parc 55, level 4

All Biotech Showcase attendees are invited to pick up name badges prior to the beginning of the conference on Monday.

SCHEDULE

BIOTECH SHOWCASE 2018 - SUNDAY REGISTRATION - 07/01/2018

Biotech Showcase

January 8-10, 2018

HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

TIME	
3:00PM	3:00pm - Registration Opens

SESSIONS

BIOTECH SHOWCASE 2018 - AGENDA - DAY 1 - 08/01/2018

Biotech Showcase

January 8–10, 2018
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Continental Breakfast – Hilton Union Square

7:00am - 8:00am
Networking

Grand Ballroom

Registration Open – Hilton Union Square

7:00am - 6:00pm
Registration

Plaza A, Lobby Level

Please note: The registration desk will be open all day.

The microbiome: Beyond the gut – Hilton Union Square

8:00am - 9:00am
Workshops and Panels

Imperial Ballroom

In recent years, the bacterial communities living in and on our bodies have captivated scientists and the public alike. The gut microbiome has been tied to diverse functions and linked to both health and disease. Researchers now know that the gastrointestinal tract is just one of the many microbial homes on the human body and has a direct and measurable influence on both the central nervous and immune system. Even sites once considered sterile revealing themselves to be hotbeds of diversity with potential for addressing therapeutic needs.

Participants

Moderator: Joseph Gulfo - Executive Director, The Lewis Center for Healthcare Innovation and Technology

Panelist: Thomas Hallam - CEO, Leading BioSciences

Panelist: Arpita Maiti - Senior Director, External Science & Innovation (ES&I), Inflammation and Immunology and Microbiome, Worldwide Research and Development, Pfizer, Inc.

Panelist: Glenn Nedwin - CEO and President, Second Genome

One-to-one meetings – Hilton Union Square

8:00am - 6:00pm
Networking

Grand Ballroom

Please note: One-to-one meetings will take place all day depending on your partnering schedule.

Next generation CARs and other cell-based immunotherapies – Parc 55

8:00am - 9:05am
Additional Programming: Cell and Gene Therapies
State of the Industry Briefing

Parc 55, Level 4, Cyril Magnin Ballroom

8:00 - 8:20am Introduction and Industry Update

8:20 - 9:05am Next generation CARs and other cell-based immunotherapies

Participants

Speaker: Janet Lynch Lambert - CEO, Alliance for Regenerative Medicine

Speaker: Robet Preti - Chairman, Alliance for Regenerative Medicine; President and CEO, Hitachi Chemical Advanced Therapeutics Solutions; GM, Hitachi Chemical Regenerative Medicine Business Sector, Hitachi Chemical Advanced Therapeutics Solutions

Chair: Morrie Ruffin - Managing Partner, Adjuvant Partners; Co-Founder and Senior Advisor, Alliance for Regenerative Medicine

Panelist: Bob Azelby - Executive VP, Chief Commercial Officer, Juno Therapeutics

Panelist: Manuel Litchman - President, CEO and Director, Mustang Bio

Panelist: James Noble - CEO, Adaptimmune

Panelist: Pascal Touchon - Senior VP and Global Head, Cell and Gene, Novartis Oncology

Panelist: Scott Wolchko - President and CEO, Fate Therapeutics

Company Presentations – Hilton Union Square

8:30am - 12:00pm
Company Presentations

Yosemite A–C; Franciscan A–D

Entering the Golden Age of dermatology: It's more than skin deep – Hilton Union Square

9:00am - 10:00am
Workshops and Panels

Imperial Ballroom

Medical dermatology has entered a new and innovative era that goes beyond reformulations of existing therapies and is seeing the emergence of new companies focused on improving the care of patients whose skin diseases have substantial systemic consequences. In fact, as we see a number of emerging companies in this space focused on different therapeutic approaches, with different modalities and delivery methods, one can say that we are entering the golden age of dermatology—an area that has seen few developments in decades.

Participants

Moderator: Jennifer Friel Goldstein - Market Manager, Silicon Valley Bank

Panelist: Weston Daniel - Director, Program Management, Exicure, Inc.

Panelist: Alan Dunton - Senior VP of Research, Development and Regulatory Affairs, Purdue Pharma L.P.

Panelist: Jennifer Good - President and CEO, Trevi Therapeutics

Panelist: Shelley Hartman - CEO, Aegle Therapeutics Corporation

Panelist: Mark Wilson - Co-Founder and CEO, MatriSys Bioscience, Inc.

Gene Therapy: The outlook in 2018 – Parc 55

9:05am - 9:50am
Additional Programming: Cell and Gene Therapies
State of the Industry Briefing

Parc 55, Level 4, Cyril Magnin Ballroom

Participants

Chair: Martha Rook - Head, Gene Editing and Novel Modalities, MilliporeSigma

Panelist: Bill Lundberg - CSO, CRISPR Therapeutics

Panelist: Sandy Macrae - President and CEO, Sangamo Therapeutics

Panelist: Geoff Nichol - Senior VP, Global Clinical Development and Chief Medical Officer, BioMarin Pharmaceutical

Panelist: Amber Salzman - President and CEO, Adverum Biotechnologies

SESSIONS

BIOTECH SHOWCASE 2018 - AGENDA - DAY 1 - 08/01/2018

Biotech Showcase

January 8–10, 2018
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Lunch Plenary: The future of biotechnology and life sciences sector: Are we at a tipping point? – Hilton Union Square

12:00pm - 1:45pm
Workshops and Panels

Imperial Ballroom

The biopharmaceutical industry is often criticized for putting profit above patient welfare. But scientific advances are now leading to a surge in breakthrough medicines that should remind people of the pivotal role the industry has always played in improving the length and quality of patient lives. The promise of this surge in scientific innovation, however, won't be fully realized unless it can be matched with innovation in how drug companies bring products to market—with a focus on increasing efficiency and speed while reducing costs.

This is critically important because unlike any previous time in history, stakeholders in the healthcare ecosystem—patients, providers, intermediaries, and industry— are reimagining how health care will be delivered in the future. And this requires a serious rethinking of current business and operational models to come up with something better suited to the future marketplace. Where does the biopharmaceutical industry go from here?

Participants

Moderator: Sara Radcliffe - President and CEO, California Life Sciences Association (CLSA)

Panelist: Ron Cohen - President and CEO, Acorda Therapeutics, Inc.

Panelist: Jim Greenwood - President and CEO, Biotechnology Innovation Organization (BIO)

Panelist: Rachel King - CEO, GlycoMimetics, Inc.

Panelist: Paul Mignon - President and Global Head, Selling Solutions, Syneos Health

Panelist: Lesley Stolz - Head, JLABS California, JLABS @SSF

Company Presentations – Hilton Union Square

1:45pm - 5:30pm
Company Presentations

Yosemite A–C; Franciscan A–D

The impact of new leadership and new initiatives at FDA – Hilton Union Square

3:30pm - 4:30pm
Workshops and Panels

Imperial Ballroom

It's not just a new Administration, but also the organic evolution of FDA. This panel of veterans who've worked for, with, and across the table from FDA will discuss how things are changing and how they're staying the same. Topics include the impact of Executive Branch and Congressional politics on FDA, initiatives to address the cost and predictability of drug development and review, risk-based approaches to regulation, and keeping pace with scientific and technological advances.

Participants

Moderator: Philip Katz - Partner, Head of FDA Pharmaceutical and Biotechnology Practice, Hogan Lovells

Panelist: Nancy Bradish Myers - President, Catalyst Healthcare Consulting, Inc.

Panelist: David Horowitz - Partner, Hogan Lovells (formerly Deputy General Counsel at HHS and Head of the Office of Compliance for Drugs at FDA)

Panelist: John Jenkins - Principal, Greenleaf Health (formerly Director, Office of New Drugs at FDA)

Panelist: Gayatri Rao - Outgoing Director, Office of Orphan Products Development, FDA

The public markets and biotech: What to expect in 2018 – Hilton Union Square

4:30pm - 5:15pm
Workshops and Panels

Imperial Ballroom

Overall, the biotechnology sector performed well in 2017 and, according to various observers of this space, there are many reasons to expect good performance in 2018. Will the IPO market continue to be robust? Will we see a pick-up in M&A activity? Will new money continue to flow into this space?

Participants

Moderator: Barbara Ryan - Founder, Barbara Ryan Advisors

Panelist: Gabriel P. Cavazos - Managing Director, Investment Banking, Leerink Partners LLC

Panelist: Asthika Goonewardene - Senior Biotechnology Analyst, Bloomberg Intelligence

Panelist: Kris Jenner - Partner, Rock Springs Capital

Panelist: John Nolan - Managing Director, WBB Asset Management

Panelist: Josh Scheinfeld - Managing Member, Lincoln Park Capital, LLC

SCHEDULE

BIOTECH SHOWCASE 2018 - AGENDA - DAY 1 - 08/01/2018

Biotech Showcase

January 8–10, 2018
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

TIME	ADDITIONAL PROGRAMMING: CELL AND GENE THERAPIES STATE OF THE INDUSTRY BRIEFING	COMPANY PRESENTATIONS	NETWORKING	REGISTRATION	WORKSHOPS AND PANELS
7:00AM			7:00am - Continental Breakfast – Hilton Union Square	7:00am - Registration Open – Hilton Union Square	
8:00AM	8:00am - Next generation CARs and other cell-based immunotherapies – Parc 55	8:30am - Company Presentations – Hilton Union Square	8:00am - One-to-one meetings – Hilton Union Square		8:00am - The microbiome: Beyond the gut – Hilton Union Square
9:00AM	9:05am - Gene Therapy: The outlook in 2018 – Parc 55				9:00am - Entering the Golden Age of dermatology: It's more than skin deep – Hilton Union Square
10:00AM					
11:00AM					
12:00PM					12:00pm - Lunch Plenary: The future of biotechnology and life sciences sector: Are we at a tipping point? – Hilton Union Square
1:00PM		1:45pm - Company Presentations – Hilton Union Square			
2:00PM					
3:00PM					3:30pm - The impact of new leadership and new initiatives at FDA – Hilton Union Square
4:00PM					4:30pm - The public markets and biotech: What to expect in 2018 – Hilton Union Square

SESSIONS

BIOTECH SHOWCASE 2018 - AGENDA - DAY 2 - 09/01/2018

Biotech Showcase

January 8–10, 2018
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Registration Open – Hilton Union Square

7:00am - 6:00pm
Registration

Plaza A, Lobby Level

Please note: The registration desk will be open all day.

Continental Breakfast – Hilton Union Square

7:00am - 8:00am
Networking

Grand Ballroom

The metabolic syndrome epidemic – Hilton Union Square

8:00am - 9:00am
Workshops and Panels

Yosemite B

Metabolics as a therapeutic area is evolving through expansion into adjacent diseases such as obesity, NASH and hypertension. This broadening of focus is a means for continued innovation and return on investment. As companies begin to understand the underlying links between type 2 diabetes and its comorbidities, there is a greater investment in expanding a traditionally narrow-focused portfolio. Recently, NASH appears to be the most promising indication with many players in development, an increase in deal flow, and a rise in investor interest. However, there are challenges around how to demonstrate clinical and economic value. Join us for an interactive discussion around these topics.

Participants

Moderator: Philip Kenner - Principal, ClearView Healthcare Partners

Panelist: Brian T. Bloomquist - Senior Director, Diabetes External Innovation, Eli Lilly and Company

Panelist: Deborah Dunsire - CEO and President, XTuit

Panelist: Michael Graffeo - Senior Partner, Graffeo & Associates

Panelist: Tomas Landh - Innovation Sourcing VP, Senior Principal Scientist, Innovation Sourcing, Novo Nordisk

Panelist: Harith Rajagopalan - Co-Founder and CEO, Fractyl Laboratories

Panelist: Ken Song - President and CEO, Metacrine Inc.

One-to-one meetings – Hilton Union Square

8:00am - 6:00pm
Networking

Grand Ballroom

Please note: One-to-one meetings will take place all day depending on your partnering schedule.

Company Presentations – Hilton Union Square

8:30am - 12:00pm
Company Presentations

Yosemite A–C; Franciscan A–D

Infectious disease in the age of resistance – Hilton Union Square

9:00am - 10:00am
Workshops and Panels

Yosemite B

Anti-microbial drug development has received renewed enthusiasm from select companies after a drought of new marketing approvals for a decade and a half, spurred by the emergence of anti-microbial resistance (AMR) as a key public health concern highlighted both by the WHO globally and the CDC in the US, as well as renewed interest from biotech companies and investors. The panelists assembled are at the leading edge of anti-microbial drug development and will discuss the tailwinds and headwinds in the space, what it takes to get an anti-bacterial or anti-fungal drug approved, how to create a successful commercially sustainable business and what is exciting in the pipeline.

Participants

Moderator: Bibhash Mukhopadhyay - Principal, New Enterprise Associates

Panelist: Alan Carr - Senior Analyst, Biotechnology, Needham & Company, LLC

Panelist: Julia Gregory - Former CEO, Contrafact

Panelist: Kenneth Hillan - CEO, Achaogen

Panelist: Gregory G. Mario - CEO, TAXIS Pharmaceuticals, Inc

Panelist: John Rex - Chief Medical Officer and Director, F2G, Ltd; Expert-in-Residence, Wellcome Trust; Operating Partner, Advent Life Sciences

Panelist: Chris Stevens - Chief Medical Officer, Arsanis

Lunch Plenary: What it means to be in the era of cures – Hilton Union Square

12:00pm - 1:45pm
Workshops and Panels

Imperial Ballroom

From Sovaldi to CAR-T, and immuno-oncology to gene therapy, the biotechnology industry is shifting the focus of product development from treatments to cures. Still playing catch-up are our public and private markets, whose current mechanisms for coverage, pricing, and liability are designed for maintenance therapy and single-indication treatments. The resulting mismatch between current regulatory schemes and new curative therapies makes even more complex the already difficult and expensive early-stage decisions regarding what product candidates to pursue. Hear how stakeholders are considering these factors and risks as they identify, develop, and commercialize products that are transforming the future of the industry.

Participants

Moderator: Alice Valder Curran - Partner, Hogan Lovells

Panelist: Eric Aguiar - Partner, Aisling Capital LLC

Panelist: Philippe Lopes-Fernandes - Senior VP, Head of Global Licensing and Business Development, Merck KGaA

Panelist: Camille Samuels - Partner, Venrock

Panelist: Pascal Touchon - Senior VP and Global Head, Cell and Gene, Novartis Oncology

Panelist: Robert E. Ward - Chairman and CEO, Eloxx Pharmaceuticals

Company Presentations – Hilton Union Square

1:45pm - 5:30pm
Company Presentations

Yosemite A–C; Franciscan A–D

SESSIONS

BIOTECH SHOWCASE 2018 - AGENDA - DAY 2 - 09/01/2018

Biotech Showcase

January 8–10, 2018
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Data as the new rocket fuel for healthcare investing – Hilton Union Square

3:30pm - 4:30pm
Workshops and Panels

Imperial Ballroom

The last several years have seen an upsurge of investments in companies that are aggregating data and performing analytics instead of (or in addition to) directly helping patients. The allure of AI and machine learning has begun to further energize this space. What do data-focused companies plan next? How do investors think about the space?

Participants

Moderator: Steve Dickman - Founder and CEO, CBT Advisors

Panelist: Ron Alfa - VP, Discovery and Product, Recursion Pharmaceuticals

Panelist: Gary Kurtzman - Senior VP and Managing Director, Safeguard

Panelist: Katherine Merton - Head, JLABS NYC, Johnson & Johnson Innovation

Panelist: Ajit Singh - Managing Director and General Partner, Artiman Ventures

Drivers of innovation: Evolving models in rare disease drug development – Hilton Union Square

4:30pm - 5:30pm
Workshops and Panels

Imperial Ballroom

The growing pressure on drug companies to bring new rare disease therapies quickly and cost-effectively is giving rise to a variety of emerging business models. While there are a number of fully integrated pharmaceutical companies in the space, others are focusing on licensing a platform technology, acting more like an incubator, or driving an array of projects through a collaboration model. What do companies gain or lose through such strategies? How do they accelerate the development of new therapies? How do investors view these models?

Participants

Moderator: Daniel Levine - Editor, RARE Daily; Host, RARECast; Principal, Levine Media Group

Panelist: Brinda Balakrishnan - Group VP, Corporate and Business Development, BioMarin

Panelist: Sarah Boyce - Senior VP and Chief Business Officer, Ionis Pharmaceuticals, Inc

Panelist: Neil Kumar - CEO, BridgeBio

Speaker: Robert Pacifici - Chief Scientific Officer, CHDI

SCHEDULE

BIOTECH SHOWCASE 2018 - AGENDA - DAY 2 - 09/01/2018

Biotech Showcase

January 8–10, 2018
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

TIME	COMPANY PRESENTATIONS	NETWORKING	REGISTRATION	WORKSHOPS AND PANELS
7:00AM		7:00am - Continental Breakfast – Hilton Union Square	7:00am - Registration Open – Hilton Union Square	
8:00AM	8:30am - Company Presentations – Hilton Union Square	8:00am - One-to-one meetings – Hilton Union Square		8:00am - The metabolic syndrome epidemic – Hilton Union Square
9:00AM				9:00am - Infectious disease in the age of resistance – Hilton Union Square
10:00AM				
11:00AM				
12:00PM				12:00pm - Lunch Plenary: What it means to be in the era of cures – Hilton Union Square
1:00PM	1:45pm - Company Presentations – Hilton Union Square			
2:00PM				
3:00PM				3:30pm - Data as the new rocket fuel for health-care investing – Hilton Union Square
4:00PM				4:30pm - Drivers of innovation: Evolving models in rare disease drug development – Hilton Union Square

SESSIONS

BIOTECH SHOWCASE 2018 - AGENDA - DAY 3 - 10/01/2018

Biotech Showcase

January 8–10, 2018
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Registration Open – Hilton Union Square

7:00am - 5:00pm
Registration

Plaza A, Lobby Level

Please note: The registration desk will be open all day.

Continental Breakfast – Hilton Union Square

7:00am - 8:00am
Networking

Grand Ballroom

Analyst's pulse: What's hot and what's not – Hilton Union Square

8:00am - 9:00am
Workshops and Panels

Imperial Ballroom

After a relatively good year for the biotech sector, what is in store for 2018? This panel of seasoned industry analysts will share their insights on the trends they are seeing in new therapeutic developments, the areas to watch, the disruptors and the game changers.

Participants

Moderator: Mark Simon - Managing Director, Torreyia

Panelist: Steve Brozak - President, WBB Securities LLC

Panelist: Mara Goldstein - Senior Managing Director, Director of Research and Senior Analyst, Cantor Fitzgerald

Panelist: George B. Zavoico - Senior Research Analyst, Senior VP, Equity Research, Healthcare, B. Riley FBR, Inc.

One-to-one meetings – Hilton Union Square

8:00am - 5:00pm
Networking

Grand Ballroom

Please note: One-to-one meetings will take place all day depending on your partnering schedule.

Company Presentations – Hilton Union Square

8:30am - 12:00pm
Company Presentations

Yosemite A–C; Franciscan A–D

IO on the move: New targets, new trends, new combinations – Hilton Union Square

9:00am - 10:00am
Workshops and Panels

Imperial Ballroom

As immuno-oncology (IO) continues to be at the forefront of efforts to improve outcomes in cancer, even offering the possibility of curing some patients, biopharma appears more than ever before to be adopting a strategy of spreading its bets—among novel MOAs, targets, and therapeutic modalities to well-known/established targets, and to an immense array of combinations of currently approved agents, primarily checkpoint inhibitors. This panel will attempt to provide some vision into the future of this complex and dynamic space and will highlight key themes that may show us where the next wave of innovation may come, where there may be white space in the biology, and, importantly for investment in clinical development, what biopharma will be looking for from these IO-centric newcos.

Participants

Moderator: Jeffrey Bockman - Principal, Senior VP, Oncology Practice Head, Defined Health

Panelist: John Castle - Head, Translational Medicine and Bioinformatics, Agenus, Inc

Panelist: Bassil I. Dahiyat - President and CEO, Director, Xencor

Panelist: Carlos de Sousa - CEO, Immunicum

Panelist: Darren Ji - CEO, Elpiscience Pharmaceuticals, Inc.; Venture Partner, Lilly Asia Ventures

Panelist: William Newell - CEO, Sutro Biopharma, Inc.

Panelist: Jill O'Donnell-Tormey - CEO and Director of Scientific Affairs, Cancer Research Institute (CRI)

Lunch Plenary: Reflecting on 2017 record-breaking venture numbers: What's behind the surge and will it continue in 2018? – Hilton Union Square

12:00pm - 1:45pm
Workshops and Panels

Imperial Ballroom

As of November 2017, the biotech sector attracted \$9.3 billion in venture funding in 471 deals, including several mega-deals such as Unity Biotechnology and ADC Therapeutics. New funds entered the space, corporate investors increased their activity, traditional biotech venture investors added new portfolio companies to their rosters and crossover investors saw a lot that they liked as well. By far, 2017 was the best year for venture funding since 2010. This panel will discuss what was behind the 2017 surge and whether it will continue in 2018.

Participants

Moderator: Ellen B. Corenswet - Partner, Covington & Burling LLP

Panelist: Han Lee - Senior Director, Corporate Development and Ventures, AstraZeneca

Panelist: Marian Nakada - VP, Venture Investments, Johnson & Johnson Innovation

Panelist: Jonathan Norris - Managing Director, Sales Origination, Silicon Valley Bank

Panelist: Art Pappas - Managing Partner, Pappas Ventures

Panelist: Alex Zisson - Managing Director, H.I.G. Capital

Company Presentations – Hilton Union Square

1:45pm - 5:00pm
Company Presentations

Yosemite A–C; Franciscan A–D

SESSIONS

BIOTECH SHOWCASE 2018 - AGENDA - DAY 3 - 10/01/2018

Biotech Showcase

January 8–10, 2018

HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

Media roundup: Heard around the square – Hilton Union Square

4:30pm - 5:15pm
Workshops and Panels

Imperial Ballroom

As the most important week of the biotech calendar is draws to a close, join us to hear what trends and issues will reverberate in 2018. This panel of all-star reporters will provide their take on what was heard around Union Square. Who were the newsmakers? What is their analysis of the week's biggest stories? What does the industry need to prepare for next year and beyond?

Participants

Co-Moderator: Ben Bonifant - Partner, Triangle Insights Group, LLC

Co-Moderator: Barbara Ryan - Founder, Barbara Ryan Advisors

Panelist: Caroline Chen - Health Reporter, Bloomberg News

Panelist: Adam Feuerstein - Senior Writer, National Biotech Columnist, STAT

Panelist: Ron Leuty - Biotech Reporter, San Francisco Business Times

Panelist: Brittany Meiling - Senior Writer, Endpoints News

Panelist: Juliet Preston - Contributing Writer, MedCity News

Panelist: Luke Timmerman - Founder and Editor, Timmerman Report

Closing reception

5:15pm - 6:15pm

Grand Ballroom

SCHEDULE

BIOTECH SHOWCASE 2018 - AGENDA - DAY 3 - 10/01/2018

Biotech Showcase

January 8–10, 2018
HILTON SAN FRANCISCO UNION SQUARE
San Francisco, CA 94102 USA

TIME	COMPANY PRESENTATIONS	NETWORKING	REGISTRATION	WORKSHOPS AND PANELS
7:00AM		7:00am - Continental Breakfast – Hilton Union Square	7:00am - Registration Open – Hilton Union Square	
8:00AM	8:30am - Company Presentations – Hilton Union Square	8:00am - One-to-one meetings – Hilton Union Square		8:00am - Analyst's pulse: What's hot and what's not – Hilton Union Square
9:00AM				9:00am - IO on the move: New targets, new trends, new combinations – Hilton Union Square
10:00AM				
11:00AM				
12:00PM				12:00pm - Lunch Plenary: Reflecting on 2017 record-breaking venture numbers: What's behind the surge and will it continue in 2018? – Hilton Union Square
1:00PM	1:45pm - Company Presentations – Hilton Union Square			
2:00PM				
3:00PM				
4:00PM				4:30pm - Media roundup: Heard around the square – Hilton Union Square
5:00PM	5:15pm - Closing reception	5:15pm - Closing reception	5:15pm - Closing reception	5:15pm - Closing reception